Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Holdings

2,366.54
+27.761.19%
Number of Gainers:64
Number of Losers:32
Number of Flat:1
PE:- -
High:2,375.70
Open:2,338.93
Low:2,338.93
Close:2,338.78
Volume:1.50B
Turnover:303.06B
Market Cap:52.42T
Float Cap:49.11T

Loading ...

Brent (UKOIL) Is up 2.26% on Oct 1: Why It Happened

TradingKey
·
Oct 01

This Fidelity Manager Likes Coca-Cola, Keurig Dr Pepper, and Other Consumer Staples Bargains

Dow Jones
·
Oct 01

X-Rite Pantone Launches Spectura Portable Sphere Spectrophotometer Platform

Reuters
·
Oct 01

India's CAFE 3 Norms Favour EV Suppliers, Ease Compliance Burden for OEMs, Say BofA, Nomura

Reuters
·
Oct 01

Kyobo Securities Launches New Equity-Linked Bonds Tied to Samsung and SK hynix

TIPRANKS
·
Oct 01

GARO Shuts Down Entity Charger Line to Refocus on Core Electrification Business

TIPRANKS
·
Oct 01

Thales - Thales and Google Strengthen Their Partnership to Secure Agent-Based AI

THOMSON REUTERS
·
Oct 01

Tesla New Registrations in Sweden +38.4% Year-on-Year in September, Compiler Mobility Sweden Says

THOMSON REUTERS
·
Oct 01

Piper Sandler Raises Microsoft Price Target to $610, Citing Copilot and E7 as New M365 Monetization Drivers

Deep News
·
Oct 01

Goldman Sachs pushes back second Fed rate hike forecast to December, saying need for further tightening is diminishing

Deep News
·
Oct 01

Barclays (BARC) Gets a Buy from J.P. Morgan

TIPRANKS
·
Oct 01

Bayer Names Christoph Koenen Chief Medical Officer

Reuters
·
Oct 01

Pfizer Says Tilrekimig Hits Phase 2 Atopic Dermatitis Endpoint with 62.5% EASI-75 at Week 16

Reuters
·
Oct 01

Pfizer - no Serious Adverse Events Related to Tilrekimig in Phase 2 Study

THOMSON REUTERS
·
Oct 01

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

THOMSON REUTERS
·
Oct 01

Pfizer - Tilrekimig Well-Tolerated with Teae Rates Comparable to Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - 62.5% of Patients on Tilrekimig 450 Mg Q2w Achieve Easi-75 vs 19.9% Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - Phase 2 Study Meets Primary Endpoint with Significant Easi-75 Improvement at Week 16

THOMSON REUTERS
·
Oct 01

Top 3 Founder Run Stocks To Watch In October 2026

Simply Wall St.
·
Oct 01

Learn Why The Bull Case For Fastly (FSLY) Could Change Following Comcast Edge Partnership

Simply Wall St.
·
Oct 01